Categories
Articles

Konsensuspapier der DMKG

  • Post author By dmkg

.
< – Konsensuspapier

Literatur des Konsensuspapiers der DMKG:

  1. Diener HC, Brune K, Gerber W, Göbel H, Pfaffenrath V. Behandlung der Migräneattacke und Migräneprophylaxe. Dtsch Ärztebl 1997;94:A3092-A3102.
  2. Rasmussen BK. Epidemiology of headache. Cephalalgia 1995;15:44-45.
  3. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl.7):1-93.
  4. Maytal J, Young M, Shechter A, Lipton RB. Pediatric migraine and the International Headache Society (IHS) criteria. Neurology 1997;48:602-607.
  5. MacGregor EA. “Menstrual” migraine: towards a definition. Cephalalgia 1996;16:11-21.
  6. Honkasalo M, Kaprio J, Winter T, Heikkilä K, Sillanpää, Koskenvuo M. Migraine and concomitant symptoms among 8167 adult twin pairs. Headache 1995;35:70-78.
  7. Ulrich V, Gervil M, Kyvik KO, Olesen J, Russell MB. Evidence of a genetic factor in migraine with aura: a population-based danish twin study. Ann Neurol 1999;45:242-246.
  8. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SMG, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1997;87:543-552.
  9. Gardner K, Barmada MM, Ptacek LJ, Hoffman EP. A new locus for hemiplegic migraine maps to chromosome 1q31. Neurology 1997;49:1231-1238.
  10. Ducros A, Joutel A, Vahedi K, Cecillon M, Ferreira A, Bernard E, et al. Mapping of a second locus for familial hemiplegic migraine to 1q21-q23 and evidence of further heterogeneity. Ann Neurol 1997;52:885-890.
  11. Gervil M, Ulrich V, Kaprio J, Olesen J, Russell M. The relative role of genetic and environmental factors in migraine without aura. Neurology 1999;53:995-999.
  12. Nyholt DR, Lea RA, Goadsby PJ, Brimage PJ, Griffiths LR. Familial typical migraine: linkage to chromosome 19p13 and evidence for genetic heterogenity. Neurology 1998;50:1428-1432.
  13. Cooke LJ, Rose MS, Becker WJ. Chinook winds and migraine headache. Neurology 2000;54:302-307.
  14. Diener HC. Technische Zusatzuntersuchungen bei Kopfschmerzen: was ist notwendig und erforderlich? Der Schmerz 1996;10:135-139.
  15. Pilgrim AJ. The methods used in clinical trials of sumatriptan in migraine. Headache 1993;33:280-293.
  16. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992;32:177-184.
  17. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;34:923-926.
  18. The Multinational Oral Sumatriptan Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 1991;31:314-322.
  19. Wilkinson M, Pfaffenrath V, Schoenen J, Diener HC, Steiner T. Migraine and cluster headache – their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia 1995;15:337-357.
  20. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on numbers needed to treat. Cephalalgia 1998;18:532-538.
  21. Visser WH, Jaspers N, de Vriend RHM, Ferrari MD. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996;16:264-269.
  22. Kaube H, May A, Diener HC, Pfaffenrath V. Sumatriptan misuse in daily chronic headache. BMJ 1994;308:1573.
  23. Evers S, Gralow I, Bauer B, Suhr B, Buchheister A, Husstedt I-W, et al. Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. Clin Neuropharmacol 1999;22:201-206.
  24. Limmroth V, Kazawara Z, Fritsche G, Diener H-C. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. Lancet 1999;353:378.
  25. Dahlöf CGH, Mathew N. Cardiovascular safety of 5-HT1B/1D agonists – Is there a cause for concern? Cephalalgia 1998;18:539-545.
  26. Diener H, Limmroth V. Therapie der akuten Migräneattacke: Kampf der “Triptane”. Arzneimitteltherapie 1999;17:219-226.
  27. Diener H, Limmroth V. Acute management of migraine: triptans and beyond. Curr Opin Neurol 1999;12:261-267.
  28. Diener H, Kaube H, Limmroth V. Antimigraine drugs. J Neurol 1999;246:515-519.
  29. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-321.
  30. Ryan R, Elkind A, Baker CC, Mullican W, DeBussy S, Asgharnejad M. Sumatriptan nasal spray for the acute treatment of migraine. Neurology 1997;49:1225-1230.
  31. Tepper SJ, Cochran A, Hobbs S, Woessner M, on the behalf of the S2B351 Study Group. Sumatriptan suppositories for the acute treatment of migraine. Int J Clin Pract 1998;52:31-35.
  32. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998;38:184-190.
  33. Tfelt-Hansen P, Goadsby PJ. Naratriptan is effective and well tolerated in the acute treatment of migraine. Neurology 1999;52:1300-.
  34. Salonen R. Naratriptan. Int J Clin Pract 1999;53:552-556.
  35. Schoenen J, Sawyer J. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. Cephalalgia 1997;17 Suppl 18:28-40.
  36. Klein KB. A review of the efficacy of zolmitriptan (311C90): a new treatment for migraine. In: Olesen J, Tfelt-Hansen P, editors. Frontiers in Headache Research Headache and Treatment: Trial Methodology and New Drugs. New York: Lippincott-Raven; 1997. p. 6:263-266.
  37. The International 311C90 Long-Term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache 1998;38:173-183.
  38. Ahrens SP, Farmer MV, Williams DL, Willoughby E, Jiang K, Block GA, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia 1999;19:525-530.
  39. Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block G, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 and 50 mg in migraine. Headache 1998;38:737-747.
  40. Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998;38:748-755.
  41. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD, et al. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch. Neurol. 1997;53:1132-1137.
  42. Diener HC. Evidence for the improved efficacy and safety of eletriptan compared with sumatriptan. Cephalalgia 1997;17:477.
  43. Pryse-Philips W, on behalf of the Eletriptan Steering Committee. Comparison of oral eletriptan (RelpaxTM) (40-80 mg) and oral sumatriptan (50-100 mg) for the treatment of acute migraine. A randomised, placebo controlled study in sumatriptan-naive patients. 9th Congress of the International Headache Society, Barcelona 1999.
  44. Steiner TJ, on behalf of the Eletriptan Steering Committee. The efficacy, saftey and tolerability of oral eletriptan (40 mg and 80 mg) for the acute treatment of migraine: results of a double-blind, placebo-controlled, parallel group clinical trial. Migraine Trust, London 1998.
  45. Dahlöf C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993;13:166-171.
  46. Tfelt-Hansen P, Saxena PR, Dahlöf C, Pascual J, Lainez M, Henry P, et al. Ergotamine in the acute treatment of migraine. A review and European consensus. Brain 2000;123:9-18.
  47. Reeches A, on behalf of the Eletriptan Steering Committee. Comparison of the efficacy, safety and tolerability of oral eletriptan (RelpaxTM) and Cafergot for the acute treatment of migraine. In: 9th Congress of the International Headache Society; 1999; Barcelona; 1999.
  48. Massiou H, on Behalf of the Study Group. A comparison of sumatriptan nasal spray 20 mg and intranasal dihydroergotamin in the acute treatment of migraine. Poster, 3rd European Headache Conference, Sardinia 1996:56-59.
  49. Touchon J, Bertin L, Pilgrim AJ, Ashford E, Bès A. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996;47:361-365.
  50. Winner P, Ricalde O, Le Force B, Saper J, Margui B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch. Neurol. 1996;53:180-184.
  51. Dichgans J, Diener HC, Gerber WD, Verspohl EJ, Kukiolka H, Kluck M. Analgetika-induzierter Dauerkopfschmerz. Dtsch med Wschr 1984;109:369-373.
  52. Volans GN. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 1975;2:57-63.
  53. Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine headache. Annals of Emergency Medicine 1993;22:191-195.
  54. Limmroth V, Katsarava Z, Diener H-C. Acetylsalicylic acid in the treatment of headache. Cephalalgia 1999;19:545-551.
  55. Pradalier A, Chabriat H, Danchot J, Baudesson G, Joire JE. Safety and efficacy of combined lysine acetylsalicylate and metoclopramide: repeat intakes in migraine attacks. Headache 1999;39:125-131.
  56. Havanka-Kanniainen H. Treatment of acute migraine attack: ibuprofen and placebo compared. Headache 1989;29:507-509.
  57. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia 1995;15:531-535.
  58. Lipton RB, Stewart WF, Ryan RE, Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain – Three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998;55:210-217.
  59. Tfelt-Hansen P, Henry P, Mulder LJ, Schaeldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346:923-926.
  60. The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999;19:232-240.
  61. Treves TA, Streiffler M, Korczyn AD. Naproxen sodium versus ergotamine tartrate in the treatment of acute migraine attacks. Headache 1992;32:280-282.
  62. Andersson PG, Hinge HH, Johansen O, Andersen CU, Lademann A, Gotzsche PC. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. Cephalalgia 1989;9:29-32.
  63. Krymchantowski AV, Adriano M, Fernandes D. Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia 1999;19:186-187.
  64. Myllyla VV, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 1998;38:201-207.
  65. Diener HC, for the ASASUMAMIG Study Group. The efficacy and safety of intavenous acetylsalicyclic lysinate compared to subcutaneous sumatritpan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomised, multicenter, parallel group study. Cephalalgia 1999;19:581-588.
  66. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Neurology 1995;45:585-587.
  67. Fisher MA, Glass S. Butorphanol (Stadol): A study in problems of current drug information and control. Neurology 1997;48:1156-1160.
  68. Silberstein SD. Headaches and women: Treatment of the pregnant and lactating migraineur. Headache 1993;33:533-540.
  69. Erush SC. The pharmacotherapy of migraine in pregnancy. Cephalalgia 1996;16:556-564.
  70. Silberstein SD. Migraine and pregnancy. Neurol Clin 1997;1:209-231.
  71. Überall MA, Wenzel D. Intranasal sumatriptan for the acute treatment of migraine in children. Neurology 1999;52:1507-1510.
  72. Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991;31:333-340.
  73. Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia 1984;4:91-96.
  74. Olsson JE, Behring HC, Forssman B, Hedman C, Hedman G, Johansson F, et al. Metoprolol and propranolol in migraine prophylaxis: a double-blind multicenter study. Acta Neurol Scand 1984;70:160-168.
  75. Sorensen PS, Larsen BH, Rasmussen MJK, Kinge E, Iversen H, Alslev T, et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991;31:650-657.
  76. Steiner TJ, Joseph R, Hedman C, Clifford Rose F. Metoprolol in the prophylaxis of migraine: parallel group comparison with placebo and dose-ranging follow-up. Headache 1988;28:15-23.
  77. van de Ven LLM, Franke CL, Koehler PJ, on behalf of the Investigators. Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. Cephalalgia 1997;17:596-599.
  78. Wörz R, Reinhardt-Benmalek B, Grotemeyer KH, Foh M. Bisoprolol and metoprolol in the prophylactic treatment of migraine with and without aura – a randomized double-blind cross-over multicenter study. Cephalalgia 1991;11 Suppl 11:152-153.
  79. Holroyd KA, Penzien DB, Rokicki LA, Cordingley GE. Flunarizine vs propranolol: a metaanalysis of clinical trials. Headache 1992; 32:256
  80. Arnold G, Einhäupl KM. Valproinsäure in der prophylaktischen Behandlung der Migräne. Nervenarzt 1998;69:913-918.
  81. Diener HC, Gendolla A, Limmroth V. Valproinsäure in der Migräneprophylaxe. Akt Neurol 1996;23:265-268.
  82. Klapper J, on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17:103-108.
  83. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-286.
  84. Silberstein SD. Methysergide. Cephalalgia 1998;18:421-435.
  85. Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996;16:257-263.
  86. Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, et al. Magnesium in the prophylaxis of migraine – a double-blind, placebo-controlled study. Cephalalgia 1996;16:436-440.
  87. Steiner TJ, Findley LJ, Yuen AWC. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997;17:109-112.
  88. Bussone G, Cerbo R, Martucci N, Micieli G, Zanferrari C, Grazzi L, et al. Alpha-dihydroergocryptine in the prophylaxis of migraine: a multicenter double-blind study versus flunarizine. Headache 1999;39:426-431.
  89. Andrasik F. Behavioral mangement of migraine. Biomedicine and Pharmacotherapy 1996;50:52-57.
  90. Hermann C, Kim M, Blanchard EB. Behavioural and prophylactic intervention studies of pediatric migraine: an exploratoy meta-analysis. Pain 1995;60:239-256.
  91. Holroyd KA, Penzien DB. Pharmacological versus non-pharmacological prophylaxis of recurrent migraine headache: a meta-analytic review of clinical trials. Pain 1990;42:1-13.
  92. Holroyd KA, Penzien DB. Psychosocial interventions in the management of recurrent headache disorders: overview and effectiveness. Behavioral Medicine 1994;20:53-63.
  93. Reid GJ, McGrath PJ. Psychological treatments for migraine. Biomedicine and Pharma-cotherapy 1996;50:58-63.
  94. Jacobson E. Progressive relaxation. Chicago: University of Chicago Press; 1938.
  95. Gauthier JG, Carrier S. Long-term effects of biofeedback on migraine headache: A prospective follow-up study. Headache 1991;31:605-612.
  96. Gerber WD, Miltner W, Gabler H, Hildenbrandt E, Larbig W. Bewegungs- und Sporttherapie bei chronischen Kopfschmerzen. In: Gerber WD, Miltner W, Mayer K, editors. Verhaltensmedizin: Ergebnisse und Perspektiven interdisziplinärer Forschung. Weinheim: edition medizin; 1987. p. 55-66.
  97. Darling M. Exercise and migraine: a critical review. J Sports Med Phys Fit 1991;31:294-302.
  98. Taubert K. Transkutane elektrische Nervenstimulation (TENS) bei Kopf- und Gesichtsschmerzen. Z Ärztl Fortbild 1991;85:31-36.
  99. Taubert K. Grundlagen für den Einsatz von Physiotherapie bei primären Kopfschmerzen. Z Ärztl Fortbild 1991;85:19-22.
  100. Walach H, Haeusler W, Lowes T, Mussbach D, Schamell U, Springer W, et al. Classical homeopathic treatment of chronic headaches. Cephalalgia 1997;17:119-126.
  101. Whitmarsch TE, Coleston-Shields DM, Steiner TH. Double-blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine. Cephalalgia 1997;17:600-604.
  102. Ernst E. Homeopathic prophylaxis of headache and migraine. A systematic review. J Pain Symptom Manage 1999;18:353-357.
  103. Melchart D, Linde K, Fischer P, White A, Allais G, Vickers A, et al. Acupuncture for recurrent headaches: a systematic review of randomized controlled trials. Cephalalgia 1999;19:779-786.
  104. Mayer H, Ditzinger G, Knoblauch P, Richter C. Feverfeweine Alternative bei Migräne. PZ Pharmazie 1992;19:26-32.
  105. Ferrari MD. The war of the triptans. In: EFNS Conference; 1999; Lisabon; 1999.

DMKG